Genmab — Oktober 2020

[Solsen]

I belive it would be worth trying to make a 50/50 collaboration with ADC. The abstract from solid cancers are very exciting in my view.

[E_L]

well , 50/50 seems to be Jan's favourite number, so who knows And I can't really remember him mentioning the number 0

[SEACOP]

Genmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting.

[SEACOP]

https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-be-presented-sitc-35th-anniversary-annual

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

Genmab
@Genmab

We’re excited to share updates from Genmab’s pipeline at the virtual #SITC2020, including first-in-human data on a bispecific antibody in joint development with https://ir.genmab.com/news-releases/

[Sukkeralf]

Lad os håbe Novartis begynder at tage markedsandele med Kesimpta, for Ocrevus kører bare derudaf: Roche Q3 sales for Ocrevus: CHF 1.2 billion, up 37%

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Sukkeralf]

Ocrevus begynder at ligne et 5 milliard dollar drug - bare GSK i sin tid havde sat mere fart over feltet

[Helge_LarsenPI-redaktør]

Tak Sukker. Det er imponerende.

[E_L]

It appears we had a real scoop here yesterday with those SITC abstracts... I was already surprised they were hours early, and even more surprised we could see the content... it seems to have been a mistake lol

[Sukkeralf]

I was also wondering about that because it should have been at late last night at kl 23 and only titles

[E_L]

exactly lol. the links also don't work anymore

[E_L]

and Society for Immunotherapy of Cancer
@sitcancer
suddenly started following me on twitter; they are on to me !

[Bulder]

[Solsen]

Det var spændende data på GEN1046, men vi må vente med at se hvor gode de egentlig er. Mange ots kun behandlet e

[Solsen]

Mange patienter kun behandlet kort tid og flere med meget små doser.

[Solsen]

Ja Ocrevus er vild. Også spændende hvad Novartis kan gøre ved Roche.

[E_L]

just checked we have to wait till oct27 for Novartis Q3 to get the first glimpse

[E_L]

New trial: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT04586426